A reference for fielding calls, texts, and emails about hormone therapy. Each tab gives you what to ask, what's likely happening, when to handle it yourself, and when to involve a provider — anchored in current evidence so you can push back on outdated advice without gaslighting the patient.
Patient Context
Optional — set to filter guidance across all tabs
01
Symptom Triage
When a patient calls, texts, or emails about hormone therapy, find the closest symptom card below. Each card walks you through what to ask, what's likely going on, and whether to handle it yourself or escalate. Cards highlighted in pink match the flags you've checked above.
●
Unscheduled Bleeding
Spotting, breakthrough, or any bleeding the patient wasn't expecting on HRT.
Ask
When did the bleeding start, and how long has it lasted?
How heavy — spotting, light flow, or like a period?
How long have you been on your current regimen, and have we changed your dose recently?
Are you taking your progesterone exactly as prescribed?
Any history of fibroids, polyps, or abnormal Paps?
Green — Handle on call
First 6 months on HRT or within 3 months of a dose change, intermittent spotting/light bleeding, no risk factors. Common and usually resolves with progestogen adjustment. Reassure, document, schedule routine follow-up. BMS '24
Amber — Schedule with provider this week
Bleeding persisting beyond 6 months on stable HRT, recurring after previously settling, heavy bleeding, or any concerning context (BMI > 30, family history of endometrial/colon cancer, Tamoxifen use, diabetes). Provider will likely order TVUS. BMS '24
Red — Escalate today
Heavy bleeding with clots, bleeding plus pelvic pain, fever, dizziness, or pregnancy-possible patient. Get a provider on the phone same-day. Hemodynamically unstable → ED.
Bleeding can feel scary, and I get why you called. Some spotting in the first 3 to 6 months of hormone therapy is actually really common — your uterine lining is adjusting to the new signal. I'm going to put a note for the provider to review your case, and depending on how long you've been on therapy they may want to adjust your progesterone or order an ultrasound just to be thorough. Are you noticing any pain with it?
Never minimize. Get the timeline, document everything. The British Menopause Society 2024 algorithm: under 6 months → adjust progestogen; over 6 months → image.
Why this is usually not cancer
The risk of endometrial cancer in women with unscheduled bleeding on HRT is significantly lower than the risk in women with postmenopausal bleeding not on HRT. The progestogen is doing its protective job. Most bleeding is mechanical — endometrium adapting to the hormonal signal. BMS '24
⚖
Weight Changes
"I'm gaining weight on HRT" — one of the most common and most misunderstood concerns.
Ask
How much weight, over what timeframe?
Where on the body — belly/midsection, or all over?
Any change in appetite, sleep, energy, or stress?
When did this start in relation to starting HRT?
Any new medications (GLP-1s, antidepressants, steroids)?
What the evidence actually says
Menopausal hormone therapy does not cause weight gain. Multiple prospective cohorts (OsteoLaus, Danish Osteoporosis Prevention Study) show HRT prevents the menopause-associated gain in visceral fat and may attenuate total fat mass gain. OsteoLausSites '05
What's actually happening: estrogen decline at menopause drives a redistribution of fat to the abdomen (visceral fat goes from ~5–8% to 15–20% of total fat in postmenopausal women). HRT counteracts this. The patient is conflating menopause-driven weight changes with the start of HRT.
Green — Handle on call
Modest weight changes (under 5–7 lbs), clear stressors or lifestyle changes, normal energy and sleep. Reassure with the evidence above, suggest dietary/movement check-in. Document.
Amber — Schedule
Rapid gain (10+ lbs in < 6 months), fluid retention pattern, brain fog, fatigue, hair changes — consider thyroid recheck or hormone reassessment. Schedule routine follow-up. Could also be GLP-1 conversation if metabolic.
I hear this concern a lot, and I want to share something most patients don't know: HRT actually prevents the kind of belly weight gain that comes with menopause — there's solid research on that. What you're feeling is real, but it's almost certainly the menopause itself, not the therapy. Let's get you in for a quick check-in — sometimes thyroid or stress is the real driver.
Never validate "HRT made me gain weight" — it's not what the data shows. Validate the experience while reframing the cause.
⚡
Fatigue
Persistent tiredness — could be hormonal, thyroid, sleep-driven, or nutrient/metabolic.
Ask
When did the fatigue start, and how would you describe it — physical, mental, or both?
How is your sleep — falling asleep, staying asleep, restorative?
Any cold intolerance, hair shedding, constipation, or dry skin? (thyroid signals)
Any change in mood, libido, or motivation? (hormonal signals)
Persistent > 2 weeks, interfering with function, accompanied by other symptoms. Provider visit for full hormone/thyroid workup.
Red — Same-day
Fatigue + chest pain, shortness of breath, leg swelling, syncope, or new severe headache. Cardiac/PE/CNS workup, not a hormone call.
Fatigue is one of those symptoms that can come from a few different places — thyroid, hormones, sleep, stress, or sometimes nutrition. Tell me a little more about the pattern — is it more morning, afternoon, or all day? And how is your sleep? That'll help us figure out where to start looking.
Don't promise it's "definitely your hormones." Triage first. Most fatigue calls need a provider visit.
New or worsening emotional symptoms on or around hormone therapy.
Ask
What's the symptom — anxious, low, irritable, tearful, "rage"?
When did it start? Before or after starting/changing HRT?
Cyclic pattern, or constant?
Are you taking your progesterone, and at what time of day?
Any thoughts of harming yourself? (always ask, document, escalate if yes)
Progesterone intolerance is real
Most patients find micronized progesterone calming and sleep-supportive (via the GABA-active metabolite allopregnanolone). A subset experience the opposite — anxiety, agitation, low mood, or sleep disruption. This is paradoxical progesterone intolerance, not a "side effect to push through."
Options for these patients: vaginal route (lower systemic absorption), LNG-IUD for endometrial protection, or in some cases switching to estrogen-alone if hysterectomy is in their past.
Amber — Schedule this week
New mood symptoms that started with HRT, especially if progesterone-related. Schedule with provider to consider route change or alternative endometrial protection.
Red — Same-day or 988
Any mention of suicide, self-harm, or wanting to "not be here." Do not end the call without a plan. 988 (Suicide & Crisis Lifeline) is appropriate to share. Get a provider on the line. Document everything.
Thank you for telling me. Mood changes can absolutely be related to hormones — and sometimes they're a sign that one piece of your regimen needs adjusting. There's a real thing called progesterone intolerance where the progesterone makes some women feel more anxious, not less. Let me get you scheduled. In the meantime, are you safe right now?
Always ask the safety question. Always.
♡
Low Libido
Low desire, reduced arousal, or distress about sexual function.
Ask
How long has this been an issue?
Is it desire, arousal, or both?
Any pain with intercourse? (GSM signal)
Relationship factors, stress, sleep, mood?
Current medications — SSRIs, beta blockers, OCPs?
The clinical model for HSDD
Hypoactive sexual desire disorder (HSDD) is the only evidence-based indication for testosterone therapy in women. The ISSWSH 2019 Global Consensus supports transdermal testosterone at doses targeting physiologic premenopausal levels. ISSWSH '19
Dr. Glaser's body of work also documents that testosterone alone relieves nearly all menopausal symptoms including hot flashes (Sherwin 1985: T > T+E2 > E2 > placebo). GlaserSherwin '85
Always rule out GSM as a contributor before assuming pure desire issue — pain with intercourse will erode desire.
Amber — Schedule
Persistent low desire with distress. Provider will workup hormone panel (Total T, Free T, SHBG, E2, DHEA-S) and discuss testosterone therapy or pellet options.
This is one of the most common things we hear and one of the most treatable. Dr. Sorr has a real specialty in this — testosterone is often a missing piece for women, and there are several routes we can take. Let me get you on the schedule. Before your visit, would you be open to running some bloodwork so we have a baseline?
Pre-pellet labs: FSH, E2, free T, total T (Glaser protocol). Confirm with provider before drawing.
Insomnia, fragmented sleep, or night-time wakings on hormone therapy.
Ask
Trouble falling asleep, staying asleep, or waking too early?
Night sweats waking you up?
Are you taking your progesterone at bedtime?
What time do you normally wake — 3am? 5am?
Caffeine, alcohol, screen use before bed?
Progesterone is a sleep tool — when timed right
Oral micronized progesterone is sedating because its metabolite allopregnanolone is GABAergic. Always take at bedtime, never in the morning. If a patient is dosing AM, that alone may be the issue.
If patient is on bedtime progesterone and still can't sleep: consider (a) night sweats from undertreated estradiol, (b) anxiety/cortisol dysregulation (3am wake-ups are classic), (c) sleep apnea (especially with weight gain or snoring).
Green — Handle on call
Patient taking progesterone in AM → switch to bedtime. Sleep hygiene basics. Recheck in 2 weeks.
Amber — Schedule
Night sweats waking patient up despite HRT — likely estradiol underdose. Cortisol pattern (3am wakings, racing thoughts) — needs broader workup. Schedule.
Real quick — what time of day are you taking your progesterone? Because it works best at bedtime; for a lot of women it's actually their sleep aid. If you're taking it in the morning, that might be the whole fix. Try it at bedtime tonight and let's see how the next few nights go.
This is a "you can fix it on the phone" call about 30% of the time. Always ask about progesterone timing first.
☀
Hot Flashes / Night Sweats
Vasomotor symptoms — either new, persistent, or returning on HRT.
Ask
How long have you been on your current dose?
How many flashes per day / night — and how severe?
Did they ever go away on HRT, and have they returned?
Are you using the patch/gel consistently?
Any patch adhesion issues, or skin reactions?
Timeline of vasomotor response
Most patients see meaningful reduction within 2–4 weeks of starting effective-dose estradiol; full effect by 8–12 weeks. If patient is < 6 weeks in, reassure and wait. NAMS '22
If patient is > 12 weeks in with persistent flashes, dose is likely insufficient. Target serum estradiol ~50–100 pg/mL for VMS control; transdermal 0.05 mg patch is often the floor, with 0.075–0.1 mg needed in some patients.
If they had relief and lost it — check patch adhesion, application site rotation, or whether the prescription was switched at the pharmacy.
Green — Handle on call
< 6 weeks on therapy, mild flashes, otherwise well. Reassure timeline. Confirm correct patch application and rotation.
Amber — Schedule
> 12 weeks on therapy with persistent flashes, or relief lost. Provider will reassess dose.
Hot flashes usually start improving by about 2 to 4 weeks and are fully under control by 2 to 3 months. If you're still in that window, we want to give it a little more time. If you're past 3 months and still flashing, we probably need to bump your dose — and that's an easy conversation. Walk me through how you're using your patch.
Application site rotation matters. Same-site daily reduces absorption over time.
◐
Breast Tenderness
Soreness, fullness, or sensitivity that started or worsened on HRT.
Ask
When did this start — within first few weeks of HRT, or out of the blue?
One side or both, generalized or focal?
Any lumps, skin changes, or nipple discharge?
Last mammogram?
How much caffeine?
Initial vs. dose-excess vs. red flag
First 2–6 weeks on HRT: Common, mild, bilateral. Tissue is responding to estrogen. Usually self-resolves.
Persistent or new tenderness after stable HRT: Often indicates dose-excess. Provider may step down the patch by one strength.
Focal, unilateral, with a lump, dimpling, nipple discharge, or skin changes: Imaging-warranted. Not an HRT issue — a breast issue.
Green — Handle on call
First 6 weeks, mild, bilateral, no focal findings. Reassure, recommend reducing caffeine, supportive bra. Recheck in 2–4 weeks.
Amber — Schedule
Persistent after 6 weeks, or new after established HRT. Provider visit to consider dose reduction.
Red — This week
Lump, dimpling, nipple discharge, skin changes, or any focal finding. Imaging-warranted regardless of HRT status. Same-week schedule.
Some breast tenderness in the first month or so is really common — the tissue is just adjusting. If it's mild and on both sides, it usually settles down. But if you're feeling a lump, or skin changes, or anything one-sided, I want to get you in sooner — that's a separate conversation from your hormones. How are you feeling about that?
Always separate the HRT question from the breast lump question. They are not the same call.
⌒
Headache
New, worsening, or pattern-changed headaches on hormone therapy.
Ask
What kind of headache — location, quality, severity?
Any visual changes, numbness, weakness, slurred speech? (aura signals)
Pattern — cyclic, around dose change, around bleed?
History of migraine, especially with aura?
What route are you on — oral, patch, gel?
Oral vs. transdermal matters
Estrogen-fluctuation headaches are more common with oral estradiol (higher peak-trough swings, first-pass effect). Steady-state transdermal often resolves them. NAMS '22
Migraine with aura is the classic red flag for systemic estrogen — historically a contraindication. Modern thinking: transdermal at low dose is increasingly considered safe in migraine-with-aura patients because it avoids the supraphysiologic peaks that drive vascular events. Always provider-decision.
Amber — Schedule
New cyclic headache pattern, dose-change correlation, or oral estradiol user with worsening headaches. Provider can switch routes or adjust.
Red — Same-day / ED
"Worst headache of my life," sudden severe onset, headache + vision loss / weakness / slurred speech / one-sided numbness. CVA workup, not a hormone call. ED.
Headaches and hormones do interact, especially around dose changes or the type of estrogen you're on. The transdermal patch is usually easier on headaches than oral. Let me get you in — but first, are you having any vision changes, weakness, or trouble speaking with the headache? Anything like that, we need to take more seriously today.
Always rule out stroke symptoms before scheduling a routine call-back.
◑
Vaginal Dryness / GSM
Genitourinary syndrome of menopause — dryness, painful intercourse, recurrent UTIs.
History of breast cancer? On tamoxifen or an aromatase inhibitor?
Local vaginal estrogen is the answer — even for many BC survivors
Local vaginal estrogen (estradiol cream, estradiol ring, estradiol tablets, or vaginal estriol) has minimal systemic absorption and is the treatment of choice for GSM. Systemic HRT does not always control GSM; many patients need local treatment added on. NAMS '22
Breast cancer survivors: Recent data show vaginal estrogen does not increase breast cancer recurrence in survivors on tamoxifen. Aromatase inhibitor users are more nuanced — recurrence data conflicting, mortality data reassuring. Vagifem 10mcg is the lowest-systemic option. Glaser also supports vaginal estriol as an even safer alternative in BC survivors. Glaser
Non-hormonal options (hyaluronic acid moisturizers, Replens) help adjunctively but don't address the atrophy.
Amber — Schedule
Any GSM symptom that bothers the patient. Highly treatable. Provider visit for local estrogen Rx.
This is one of the most treatable things in menopause, and most women don't bring it up — so I'm glad you did. We have several options including a very low-dose local cream or tablet that stays in the vaginal tissue and doesn't behave like a systemic hormone. Even patients who can't take systemic HRT can usually use it. Let me get you scheduled.
If patient has breast cancer history, do not promise anything before provider review. But reassure that there are safer local options (Vagifem 10mcg, vaginal estriol) and the conversation is worth having.
⊕
Injection Site Reaction
Redness, itching, swelling, or pain at testosterone or other injection sites.
Ask
What's at the site — itching, redness, swelling, heat, pain?
When did it start, and how long has it lasted?
Has this happened before, or is this new?
Any fever, chills, spreading redness, or systemic symptoms?
Any wheezing, throat tightness, or dizziness?
Green — Manage at home
Itch only, no heat or pain, local hives, onset 30 min – several hours, resolves in 24–48 hours, same as prior injections. Cold compress, oral antihistamine (loratadine or cetirizine), rotate sites, document.
Amber — Schedule / Pause
Getting worse with each dose, timing shifted to faster onset, spreading beyond injection zone, lasting > 48–72 hrs, or started with a new vial/lot. Pause protocol, schedule with provider for formulation review (oil/carrier switch).
Red — Seek care now
Heat + pain at site, spreading redness > 5 cm, fever or chills, pus or skin breakdown, wheezing, throat tightening, dizziness. Systemic = 911. Heat + fever + pain = ED or urgent care. Do not just add more antihistamine.
The antihistamine diagnostic test
Take a standard dose of loratadine or cetirizine when the reaction begins. Wait 60–90 minutes. Significantly better → histamine-mediated, formulation/technique issue, manageable. No improvement → something else is happening; possible infection or cellulitis, contact provider.
Walk me through what you're seeing. Is it itchy only, or is there real heat and pain there? Any fever or chills? Those last two things are important — itching and a welt is usually a histamine reaction we can manage, but heat, pain, and fever can mean infection, which is a different conversation. Try an antihistamine and see if it improves in an hour — and call us back if it gets worse or doesn't get better.
The antihistamine test is the cleanest triage. If it works, it's histamine. If it doesn't, escalate.
Reference for the estradiol conversation. What we use at SOH, why we prefer transdermal, what to say when a patient asks about safety, and where the current evidence parts ways with old dogma.
2.1
Quick Reference
SOH preferred routes
Transdermal first. Patch (Vivelle-Dot, Climara, Minivelle) or gel (Estrogel, Divigel) — bypasses first-pass hepatic metabolism, neutral on VTE risk, more physiologic estradiol-to-estrone ratio. NAMS '22ESTHER
Oral reserved for patient preference where transdermal isn't tolerated, or where patch adhesion fails consistently. Always discuss the VTE tradeoff.
Local vaginal for GSM — independent of systemic regimen, can be added on. Vagifem 10mcg or vaginal estriol preferred when systemic concern exists.
Route
Typical Starting Dose
Approx Serum E2
Notes
Patch
0.025–0.05 mg / day (twice weekly)
35–55 pg/mL
Vivelle-Dot, Climara, Minivelle. Rotate sites.
Gel
0.5–1.0 mg / day
40–80 pg/mL
Estrogel, Divigel. Apply to clean dry skin, wash hands.
No. Multiple cohort studies (OsteoLaus, Danish Osteoporosis Prevention Study) show estrogen therapy prevents the menopause-associated gain in visceral fat. Some weight gain at menopause is from declining estrogen — HRT counteracts it. OsteoLaus
"My mother had breast cancer — is HRT safe for me?"
Family history is not an absolute contraindication. Many patients with strong family history can safely use HRT, especially transdermal estradiol with micronized progesterone. Provider must review the specific family history and any genetic testing. NAMS '22
The 2024 WHI reanalysis found that estrogen alone (in hysterectomized women) actually reduced breast cancer incidence (HR 0.77) and mortality by 40%. This is the most underreported finding in the field. WHI Reanalysis '24
"How long can I stay on it?"
No arbitrary stop date. NAMS 2022 explicitly removed time-limit recommendations. Continuation is individualized — risk-benefit is reassessed periodically, but many women safely stay on HRT indefinitely if symptoms recur on discontinuation. NAMS '22
"My cardiologist / oncologist / GYN said I should stop."
Common scenario. Patient hears advice from a subspecialist that doesn't match current menopause/HRT evidence. Don't argue with the other provider in front of the patient. Get the patient in for a visit so we can review the specifics and have a collegial conversation if needed. SOH Protocol
2.3
Risks vs. Reality
The estrogen conversation is shaped by a 2002 WHI study that used conjugated equine estrogens + medroxyprogesterone acetate in women whose average age was 63. Modern evidence has separated out variables WHI conflated. Here's where to push back without overreaching.
×
Old Dogma
"All estrogen therapy increases the risk of blood clots."
✓
Current Evidence
Oral estrogen increases VTE risk 1.6–1.9× via first-pass hepatic effects on thrombin generation and activated protein C resistance. Transdermal estradiol is essentially neutral (RR ~1.0) — confirmed by ESTHER, E3N, and multiple meta-analyses. The route matters more than the molecule. ESTHERE3NMohammed/Murad '15
×
Old Dogma
"HRT causes breast cancer."
✓
Current Evidence
The signal came from CEE + medroxyprogesterone acetate. In the WHI estrogen-alone arm (hysterectomized women), estrogen reduced breast cancer incidence (HR 0.77) and breast cancer mortality by 40%. Estradiol + micronized progesterone (the modern combination) shows much weaker signal — micronized P has RR ~0.67 for breast cancer vs synthetic progestins. WHI Reanalysis '24Asi '16
×
Old Dogma
"HRT causes dementia."
✓
Current Evidence
The WHI Memory Study (WHIMS) gave HRT to women aged 65+ who were a decade past menopause — wrong window. Timing is everything. HRT initiated within 5–10 years of menopause is associated with reduced dementia risk. Late initiation (10+ years out) is where the increased risk shows up. The "critical window" hypothesis is now well-supported. APOE-ε4 carriers are an exception. Buckley '23Coughlan '23
×
Old Dogma
"HRT causes weight gain."
✓
Current Evidence
HRT does not cause weight gain. Multiple cohort studies show it prevents the menopause-associated gain in visceral fat (which goes from ~5–8% to 15–20% of total fat without intervention). The weight gain women see during the menopause transition is from declining estrogen, not its replacement. OsteoLaus
2.4
Red Flags & Escalation
!
Get a provider on the line same-day
Chest pain, shortness of breath, or new-onset cough
One-sided leg swelling, calf pain, or warmth (DVT signs)
Sudden severe headache, "worst headache of my life"
New visual changes, weakness, slurred speech, one-sided numbness
Heavy vaginal bleeding with clots, pelvic pain, fever
Unilateral breast lump, dimpling, or nipple discharge
Right upper quadrant pain (gallbladder, especially with oral estrogen)
Skin yellowing, dark urine, or pale stool (hepatic signs)
2.5
Monitoring Timeline
Timepoint
What Happens
What to Tell Patient
Week 1–2
Initial side effects peak (breast tenderness, bloating, mild headache)
"Hang in there — your body is adjusting. These usually settle by week 4."
Week 2–4
Vasomotor symptoms start improving
"Hot flashes should start easing — call us if no change by week 6."
Week 6
First check-in. Symptom review, side-effect review.
"This is when we look at whether the dose is right for you."
Month 3
Full effect on VMS; consider dose adjustment if incomplete relief
"By 3 months, you should know if this is the right dose."
Month 6
Follow-up labs if indicated. Symptom check.
"We'll repeat your labs and make sure everything is on track."
Annual
Full review. Mammogram per age-appropriate screening. Bone density per age.
"Once a year we review the whole picture and adjust as your needs change."
SOH note on serum estradiol monitoring
We do measure estradiol levels at SOH — both for dose titration and for patient reassurance. Not every practice does this. Tell patients: "We measure where your hormone level actually lands, because the dose on the patch doesn't always match what your body absorbs." SOH Protocol
03
Progesterone
Reference for the progesterone conversation. The micronized molecule, the bedtime rule, and the cleanest evidence we have for choosing micronized progesterone over synthetic progestins.
3.1
Quick Reference
SOH preferred routes
Oral micronized progesterone (Prometrium, generic) at bedtime — the default. GABA-active metabolite supports sleep; well-tolerated by most.
Vaginal micronized when oral is poorly tolerated (paradoxical anxiety, daytime sedation) — same molecule, lower systemic, direct uterine effect.
LNG-IUD (Mirena, Liletta) as an alternative endometrial protection strategy in patients who can't tolerate progesterone at all. Five-year duration.
Synthetic progestins (medroxyprogesterone, norethindrone) are NOT preferred at SOH. The breast cancer signal in WHI came from MPA; modern data favor micronized. Asi '16
Regimen
Dose
Schedule
Best For
Continuous combined
100 mg / night
Every night
Postmenopausal, want amenorrhea, established HRT
Sequential (cyclic)
200 mg / night
12–14 nights/month
Perimenopausal, still ovulating, expect a withdrawal bleed
Oral micronized progesterone metabolizes to allopregnanolone, a positive allosteric modulator at the GABA-A receptor. This is why it's sedating. Patients who take it in the morning report grogginess and "feeling drugged" — but the same dose at bedtime is one of the best sleep aids in the menopause toolkit. Always confirm timing before assuming intolerance.
3.2
Common Concerns
"It makes me anxious / agitated / depressed."
Paradoxical progesterone intolerance is real and affects a meaningful minority of patients. The mechanism is poorly understood but likely involves GABA receptor subtype variation. This is not a "push through it" side effect. Options: switch to vaginal route (lower systemic exposure), reduce the dose if continuous, or use LNG-IUD for endometrial protection. Do not insist on oral micronized in patients who feel worse on it.
"I feel groggy in the morning."
Usually means the dose is hitting too late in the night, or the patient took it too close to wake-up. Move it earlier in the bedtime window (60–90 min before sleep). If persistent, consider 100 mg instead of 200 mg, or switch route.
"Do I really need it if I had a hysterectomy?"
For endometrial protection — no. After hysterectomy, progesterone is not required for safety. However, some patients still benefit from progesterone for sleep, mood, and CNS effects. This is a quality-of-life decision, not a safety requirement. Provider discusses individually.
"Can I skip nights?"
No, not on continuous combined regimens. The progesterone is doing endometrial protection — gaps in dosing allow estrogenic stimulation without opposition, increasing breakthrough bleeding and (long-term) endometrial hyperplasia risk. If timing is a problem, address timing — not adherence.
3.3
Risks vs. Reality
The progesterone conversation is where evidence and patient anxiety diverge most. The breast cancer signal that defines public perception came from synthetic progestins — not the micronized progesterone we use. The distinction matters.
×
Old Dogma
"Progesterone causes breast cancer."
✓
Current Evidence
The breast cancer signal in WHI was from medroxyprogesterone acetate (MPA), a synthetic progestin. Micronized progesterone (the molecule we use) shows a substantially different safety profile. The Asi 2016 meta-analysis (E3N cohort + others) found RR 0.67 for breast cancer with micronized progesterone vs. synthetic progestins. Glaser's data goes further: progesterone (not synthetic progestins) does not increase breast cancer risk. Asi '16Glaser
×
Old Dogma
"Progesterone causes depression."
✓
Current Evidence
For most patients, micronized progesterone is mood-neutral or mood-supportive via GABAergic effects. A subset (estimated 10–20%) experiences paradoxical intolerance — anxiety, depression, or agitation. This is real and warrants a route change, not dismissal. Do not generalize either way. Brighten
×
Old Dogma
"All progestogens are the same."
✓
Current Evidence
They are not. Micronized progesterone is bioidentical — the same molecule the ovary makes. Synthetic progestins (MPA, norethindrone, drospirenone) are structurally different and have different receptor activity, including effects on androgen, glucocorticoid, and mineralocorticoid receptors. The cardiovascular and breast cancer signals attached to "progesterone" in the popular press are almost always traceable to synthetic progestins. NAMS '22
3.4
Red Flags & Escalation
!
Get a provider on the line this week
New or worsening depression / suicidal ideation
Severe anxiety or panic that started with progesterone
Persistent daytime sedation interfering with driving / function
Breakthrough bleeding beyond 6 months on stable regimen (see Bleeding card)
Severe breast tenderness not improving with dose adjustment
Patient skipping doses repeatedly due to side effects (adherence failure)
3.5
Monitoring Timeline
Timepoint
What Happens
What to Tell Patient
Night 1–3
Sedation effect peaks. Some grogginess possible.
"Take it 60–90 minutes before bed. You may feel drowsy at first — that's expected."
Week 1–2
Tolerance to sedation typically develops. Sleep improves.
"Most women find this is their best sleep window."
Week 4–6
If mood symptoms develop, this is when they show.
"If you're feeling more anxious or low, call us — we have other options."
Month 3
Steady state. Endometrial response established.
"By now your body is adjusted. Spotting should be settling."
Month 6
Symptom and bleeding review. Adherence check.
"We'll review your overall regimen and see if anything needs to change."
04
Testosterone
Reference for testosterone conversations across sexes. The female protocols anchor in ISSWSH and Glaser; the male protocols anchor in our internal TRT Patient Agreement and the TRAVERSE cardiovascular safety data.
4.1
Women — Quick Reference
SOH preferred routes (women)
Compounded topical testosterone cream/gel — daily, application to inner thigh or labial area, with thoughtful transfer precautions. Default first-line.
Subcutaneous testosterone pellets — for established patients who want every-3-to-4-month dosing and consistent serum levels. Glaser protocol baseline.
Compounded sublingual or buccal lozenges — used selectively. Generally not preferred due to swallowing/loss variability.
Injectable testosterone (cypionate/enanthate) — used in select cases. Avoid in patients seeking smooth profiles; injection profile has more peak/trough swing.
Glaser / hormonebalance.org reference protocol
Female pellet baseline
Duration: Pellets last 3–4 months in women, 4–5 months in men. Re-dose at symptom return, not at calendar date.
Pre-pellet labs: FSH, E2, free T, total T. SHBG and DHEA-S helpful. Provider confirms before draw.
Symptom coverage: Per Sherwin 1985, testosterone alone relieves menopausal symptoms including hot flashes — hierarchy is T > T+E2 > E2 > placebo. T-only protocols are clinically viable for many menopausal women. Sherwin '85
Aromatization concern: Add anastrozole (1 mg pellet co-implant or oral) if patient shows excess aromatization signs (breast tenderness, bleeding, mood changes) or has breast cancer history.
VTE risk: Pellets bypass the liver — they do not increase clot risk the way oral estrogens do. Glaser
Voice deepening: Not observed at therapeutic implant doses in Glaser's series. Supratherapeutic doses are a different conversation.
Target ranges (women)
Total testosterone: upper third of female reference range (~50–70 ng/dL). Some protocols target higher.
Free testosterone: upper third of female reference range.
SHBG: Important context — low SHBG means more free T per unit of total T; high SHBG (often from OCP history) sequesters T and may require higher total dosing.
At physiologic dosing — no. Voice deepening is not observed at therapeutic doses in Glaser's published series. Hirsutism (fine facial hair) is a possible side effect that resolves on dose reduction; it's not the irreversible masculinization patients fear. Voice deepening is the marker we watch for, and it's rare and dose-dependent.
"Is testosterone even approved for women?"
No FDA-approved female testosterone product exists in the United States. The ISSWSH 2019 Global Consensus supports the use of approved-male products at female doses, prescribed off-label, for HSDD. Compounded products are also used. This is a normal, evidence-supported off-label prescribing pattern in our practice. ISSWSH '19
"I have a history of breast cancer — is testosterone safe?"
This is a provider-led conversation, but the evidence is more supportive than most patients have been told. Glaser's published data show testosterone pellet (+ anastrozole to block aromatization) is safe and possibly protective in breast cancer survivors — decreases breast proliferation, lowers recurrence risk, may enhance tamoxifen efficacy. Testosterone has been used to treat breast cancer for over 80 years. Always: provider review of the specific case before any commitment. Glaser
"How long until I feel a difference?"
Libido and energy can improve within 4–6 weeks. Mood, cognition, and body composition changes take longer — often 3 months for noticeable shift. Pellet patients often describe a "click" 2–3 weeks post-insertion. Reassure patience.
4.3
Women — Red Flags
!
Schedule with provider this week
Voice deepening — even subtle. Dose review required.
Acne worsening, scalp hair shedding, or oily skin (androgenic excess)
Clitoral enlargement or discomfort
New breast tenderness or unscheduled bleeding (consider aromatization)
Elite — $375/month: Full concierge model. Priority scheduling, expanded labs, peptide and ancillary integration.
Refill rule: 14-day rule — patient must request refills with 14 days of supply remaining. Late requests are not emergency requests. Document the date.
Patient Agreement: Signed at onboarding. Covers monitoring requirements, side-effect signaling, and what happens if labs fall outside safe ranges (e.g., hematocrit > 54%).
Target ranges (men)
Total testosterone: Mid-to-upper male reference range (~600–900 ng/dL for symptom relief). Trough levels matter most on injectable protocols.
Free testosterone: Upper reference range.
Estradiol: Monitor — aromatization drives mood, libido, breast tenderness. Treat with anastrozole only if elevated and symptomatic.
Hematocrit: Watch for > 52% (caution) and > 54% (intervention — therapeutic phlebotomy or dose reduction).
PSA: Baseline and surveillance per age and risk.
4.2
Men — Common Concerns
"Does TRT cause heart attacks?"
No — and we now have the trial data to back this up. TRAVERSE (2023) randomized over 5,000 hypogonadal men with cardiovascular risk factors to testosterone or placebo. Testosterone was non-inferior to placebo for major adverse cardiovascular events (MACE). The decades-old cardiovascular fear, which came from observational data and the FDA black-box period, did not survive a properly powered RCT. TRAVERSE '23
Watch points from TRAVERSE: small but real signals for atrial fibrillation, pulmonary embolism, and acute kidney injury. Worth monitoring; not deal-breakers. Always provider-discussed.
"Will TRT shrink my testicles / kill my fertility?"
Exogenous testosterone suppresses LH/FSH and shuts down testicular testosterone and spermatogenesis. Testicular atrophy is common with sustained TRT. For fertility preservation: hCG (250–500 IU SC 2–3×/week) maintains intratesticular testosterone and spermatogenesis. Enclomiphene is an alternative for men who want endogenous T preserved without exogenous TRT.
"My estrogen is too high — should I take anastrozole?"
Not automatically. Estradiol is critical for male bone, mood, libido, and cognition. Suppressing it aggressively causes its own problems. Anastrozole is used only when E2 is elevated and the patient has aromatization symptoms (breast tenderness, water retention, mood lability). Asymptomatic high E2 is not always pathological. Provider decision.
"What about prostate cancer risk?"
Modern evidence does not support the historical fear that TRT causes or accelerates prostate cancer. The 1940s "saturation model" data has been substantially revised. We monitor PSA per age-appropriate schedule and act on changes — not on testosterone level alone.
4.3
Men — Red Flags & Escalation
!
Get a provider on the line
Chest pain, palpitations, shortness of breath, or new-onset cough (cardiac / PE signals)
One-sided leg swelling or calf pain (DVT)
New irregular heartbeat or "fluttering" (atrial fibrillation — TRAVERSE signal)
Hematocrit reported as > 54% on routine labs
Significant breast enlargement / tenderness (gynecomastia)
New mood instability, aggression, or sleep disruption
Injection site reactions (see Triage tab — antihistamine test applies)
4.4
Men — Adjunct Therapies
Adjunct
When
Typical Dose
Notes
Anastrozole
Elevated E2 + symptoms
0.25–0.5 mg 2×/week
Lowest effective dose. Crashing E2 is harmful.
hCG
Fertility / testicular preservation
250–500 IU SC 2–3×/week
Maintains intratesticular T and spermatogenesis.
Enclomiphene
Alternative to TRT (preserves HPG axis)
12.5–25 mg daily or QOD
For men prioritizing fertility / natural production.
Therapeutic phlebotomy
Hematocrit > 54%
Per blood bank protocol
Donate blood. Reassess HCT in 6–8 weeks.
05
Thyroid
Thyroid often masquerades as menopause, and menopause often masquerades as thyroid. The first job is to know which is which. This tab covers the workup, the treatment thresholds, and where the 2024 ATA update parts ways with old "TSH-only" management.
5.1
Beyond TSH — The Full Workup
What we order at SOH
TSH — the screening test. Sensitive but not sufficient.
Free T4 (fT4) — what the gland is releasing.
Free T3 (fT3) — the active hormone at tissue level. Often missing on standard panels.
Reverse T3 (rT3) — when fT3:rT3 ratio is depressed, points to peripheral conversion problems (stress, undernutrition, chronic illness).
TPO + TGAb antibodies — autoimmune thyroiditis (Hashimoto's). Often present with normal TSH and symptoms.
TSH alone misses peripheral conversion issues, autoimmune disease in the eu-thyroid phase, and central hypothyroidism. A normal TSH does not rule out a thyroid problem.
Marker
Optimal Range (functional)
Standard Lab Range
TSH
1.0–2.0 µIU/mL
0.45–4.5 µIU/mL
Free T4
1.1–1.5 ng/dL (upper half)
0.8–1.8 ng/dL
Free T3
3.2–4.2 pg/mL (upper half)
2.3–4.2 pg/mL
Reverse T3
< 15 ng/dL ideally
9.2–24.1 ng/dL
fT3:rT3 ratio
> 20 (some advocate > 14)
Not standard
TPO Ab
Negative
< 9 IU/mL
5.2
Treatment Thresholds
Overt hypothyroidism
TSH > 10 µIU/mL with low fT4 → treat. Levothyroxine (T4) first-line. Target TSH within reference, with attention to symptoms and fT3.
Subclinical hypothyroidism
TSH 4.5–10 µIU/mL with normal fT4 → individualize. ATA 2014 was conservative ("consider treatment if TSH > 10 or symptomatic"); modern functional practice often treats earlier when symptoms are present, TPO is positive, or fertility/pregnancy is a goal. ATA '14
Persistent symptoms on T4 alone
The ATA 2024 update opened the door to T4/T3 combination therapy for patients persistently symptomatic on adequate T4 — a reversal of the longstanding T4-only orthodoxy. This is the framework SOH has been using for years; it's now mainstream-supported. ATA '24
Options: liothyronine (synthetic T3) added to T4, or natural desiccated thyroid (NDT — Armour, NP Thyroid). NDT has both T4 and T3 in a ~4:1 ratio.
NDT — what to know
Patients ask about NDT often. It's a viable option for many — particularly those who feel "TSH is fine but I don't feel right." Some patients respond better to NDT than to T4 alone. Watch for: TSH suppression (some over-respond), fT3 spikes (timing matters — take in AM), and supply-chain inconsistency (Armour has had reformulation history; NP Thyroid is the alternative most clinicians prefer now).
5.3
Common Concerns
"My TSH is normal but I feel terrible."
Most common thyroid call in functional practice. TSH-only management misses peripheral conversion issues. We run the full panel — fT4, fT3, rT3, antibodies. Patient often has either (a) low fT3 with normal TSH (poor conversion), (b) positive antibodies with normal labs (early Hashimoto's), or (c) elevated rT3 from chronic stress / cortisol / illness. Provider visit.
"Is this thyroid or menopause?"
Often both, often overlapping. Fatigue, weight gain, brain fog, hair changes, mood, cold intolerance — all appear in both. We don't have to choose; we work them up together. Both can be true.
"Can HRT affect my thyroid medication?"
Yes — oral estrogen raises thyroxine-binding globulin (TBG), reducing free T4 availability. Patients starting oral estrogen may need T4 dose increase. Transdermal estrogen bypasses this — another reason to prefer the patch. Always recheck TSH and free hormones 6–8 weeks after any HRT change in a thyroid patient.
"Why iodine / selenium / etc.?"
Nutrient co-factors matter. Selenium supports T4→T3 conversion. Iodine is essential but contentious (excess can trigger autoimmune flare in some). Zinc, ferritin, and vitamin D all contribute. Patient question, provider answer — but generally we test before supplementing.
5.4
Red Flags & Escalation
!
Get a provider on the line same-day
Palpitations, chest pain, or atrial fibrillation on thyroid medication (over-replacement)
Severe agitation, insomnia, weight loss (thyrotoxicosis / Graves')
Severe fatigue, cognitive slowing, cold intolerance — uncontrolled severe hypothyroidism
First recheck after starting or changing thyroid med
TSH, fT4, fT3. Wait this long — TSH takes ~6 weeks to stabilize.
Every 8 weeks
Until stable on dose
Same panel. Adjust per symptoms + labs.
Every 6 months
Stable patient maintenance
TSH, fT4, fT3. Antibodies annually if Hashimoto's.
Annual
Full review
Full panel + clinical assessment.
After any HRT change
Re-equilibration
Recheck at 6–8 weeks — TBG shifts on oral E2.
SOH note on monitoring
We monitor functionally, not just by TSH. Patient symptoms guide titration as much as numbers. A patient with TSH 1.8 and persistent symptoms is not "done" — we look further (fT3, rT3, antibodies). A patient with TSH 0.3 and feeling great may not need a dose reduction if fT4/fT3 are in range and they're not symptomatic. Numbers in context. SOH Protocol
